Mutations in penicillin-binding protein 2 from cephalosporin-resistant Neisseria gonorrhoeae hinder ceftriaxone acylation by restricting protein dynamicsShow others and affiliations
2020 (English)In: Journal of Biological Chemistry, ISSN 0021-9258, E-ISSN 1083-351X, Vol. 295, no 21, p. 7529-7543Article in journal (Refereed) Published
Abstract [en]
The global incidence of the sexually transmitted disease gonorrhea is expected to rise due to the spread of Neisseria gonorrhoeae strains with decreased susceptibility to extended-spectrum cephalosporins (ESCs). ESC resistance is conferred by mosaic variants of penicillin-binding protein 2 (PBP2) that have diminished capacity to form acylated adducts with cephalosporins. To elucidate the molecular mechanisms of ESC resistance, we conducted a biochemical and high-resolution structural analysis of PBP2 variants derived from the decreased-susceptibility N. gonorrhoeae strain 35/02 and ESC-resistant strain H041. Our data reveal that mutations both lower affinity of PBP2 for ceftriaxone and restrict conformational changes that normally accompany acylation. Specifically, we observe that a G545S substitution hinders rotation of the β3 strand necessary to form the oxyanion hole for acylation and also traps ceftriaxone in a noncanonical configuration. In addition, F504L and N512Y substitutions appear to prevent bending of the β3-β4 loop that is required to contact the R1 group of ceftriaxone in the active site. Other mutations also appear to act by reducing flexibility in the protein. Overall, our findings reveal that restriction of protein dynamics in PBP2 underpins the ESC resistance of N. gonorrhoeae.
Place, publisher, year, edition, pages
American Society for Biochemistry and Molecular Biology, 2020. Vol. 295, no 21, p. 7529-7543
Keywords [en]
Neisseria gonorrhoeae, extended-spectrum cephalosporins, ceftriaxone, penicillin-binding protein 2, crystal structure, resistance mechanism, conformational change, peptidoglycan
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-82611DOI: 10.1074/jbc.RA120.012617ISI: 000537733500029PubMedID: 32253235Scopus ID: 2-s2.0-85085259086OAI: oai:DiVA.org:oru-82611DiVA, id: diva2:1438429
Note
Funding Agencies:
United States Department of Energy (DOE) W-31-109-ENG-38
Medical University of South Carolina's Research Resource Facilities program S10 RR027139
2020-06-102020-06-102020-12-01Bibliographically approved